Post on 06-Apr-2018
8/2/2019 Management of Non-Variceal Upper
1/24
8/2/2019 Management of Non-Variceal Upper
2/24
Introduction
UGIB is a common medical emergencyassociated with significant morbidity andmortality.
The commonest cause of UGIB is peptic ulcer disease
NSAIDS
H. pylori
Oesophatigis
Malignancy
Mallory weiss tear
8/2/2019 Management of Non-Variceal Upper
3/24
Bleeding peptic ulcer most commoncourse.
80% stop spontaneously
20% persistent/ recurrent bleeding.
8/2/2019 Management of Non-Variceal Upper
4/24
> men than women Increasing age Mortality rate from UGIB was 10.2% but increased substantially
with age and did not differ between the sexes.Inpatients that were admitted for otherdiagnosis but developed UGIB had the highestmortality; at almost 5 times higher than thosewith emergency admissions or transfers from
other hospitals for UGIB. 64% of thoseadmitted in this series had peptic ulcer diseaseas a cause of bleeding
8/2/2019 Management of Non-Variceal Upper
5/24
8/2/2019 Management of Non-Variceal Upper
6/24
8/2/2019 Management of Non-Variceal Upper
7/24
Assessment of OngoingBleeding Continuous haemetemesis or persistent
hypovolaemia despite aggressive resuscitationbleeding is still active.
Passage of fresh melaena, which is marooncoloured or passage of bright red visible clots
suggest active bleeding. The insertion of a nasogastric tube may be helpful in
demonstrating active bleeding.
However,it may be poorly tolerated.
The caveat is when there is a bleeding ulcer with the
pylorus in spasm. Aspirate without evidence of bloodor coffeee-grounds material is seen in about 15% ofpatients with UGIB.
8/2/2019 Management of Non-Variceal Upper
8/24
Risk Assessment
Risk Factors For Death After Hospital AdmissionFor Acute Upper Gastrointestinal Bleeding
1. Advanced age2. Shock on admission(pulse rate >100 beats/min;
systolic blood pressure < 100mmHg)
3. Comorbidity (particularly hepatic or renal failure anddisseminated malignancy)
4. Diagnosis (worst prognosis for advanced uppergastrointestinal malignancy)
5. Endoscopic findings (active, spurting haemorrhagefrom peptic ulcer; non-bleeding visible vessel)
6. Rebleeding (increases mortality 10 fold)
8/2/2019 Management of Non-Variceal Upper
9/24
8/2/2019 Management of Non-Variceal Upper
10/24
Endoscopy For RiskAssessment
Early upper gastrointestinal endoscopy(within 12-24 hours) is the cornerstoneof management of UGIB.
Early endoscopy has 3 major roles viz.diagnosis, treatmentandriskstratification.
It is the most accurate method availablefor identifying the source of bleeding.
8/2/2019 Management of Non-Variceal Upper
11/24
8/2/2019 Management of Non-Variceal Upper
12/24
Endoscopic therapy
8/2/2019 Management of Non-Variceal Upper
13/24
PHARMACOLOGICALTHERAPY
H2-Receptor Antagonists
A recent meta-analysis concluded that there wasno evidence to support the use of H2- receptor
antagonists in the treatment of bleedingduodenal ulcers but there is evidence of amoderate benefit in gastric ulcers
Proton Pump Inhibitors (PPIs)
High dose intravenous PPI (eg IV Omeprazole80mg stat followed by an infusion of 8mg hourlyfor 72 hours) be commenced (Grade B)
8/2/2019 Management of Non-Variceal Upper
14/24
MANAGEMENT ofREBLEEDING
Recurrent bleeding remains the singlemost important adverse prognosticfactor.
Morbidity and mortality are higher inthose with rebleeding and 95% ofrebleeding occurs within the first 72
hours of hospitalisation
R bl di Aft I iti l
8/2/2019 Management of Non-Variceal Upper
15/24
Rebleeding After InitialEndoscopic Control of
Bleeding Ulcers haemostasis is not permanent and re-bleeding occurs in about 15-20% of thecases.
In patients with peptic ulcers andrecurrent bleeding after initialendoscopic control of bleeding,endoscopic retreatment reduces the
need for surgery without increasing therisk of death and is associated withfewer complications than is surgery
8/2/2019 Management of Non-Variceal Upper
16/24
Surgery if decided upon should beperformed early rather than late to avoidan unfavorable outcome especially in
the hypotensive elderly patient. In some patients, endoscopic
appearances (eg. a giant posterior
duodenal ulcer) may suggest thatsurgery be the preferred option
8/2/2019 Management of Non-Variceal Upper
17/24
ROLE OF SURGERY
changed with wider use of endoscopichemostasis in bleeding ulcers, no longeraiming to cure the disease but primarily
to stop the hemorrhage. Mortality after urgent surgery correlates
with the preoperative Apache 2 score.
8/2/2019 Management of Non-Variceal Upper
18/24
Indications for Surgery as thePrimary Mode of Treatment Massive bleeding
Ulcer inaccessible to endoscopic control
Type of Surgery for Bleeding PepticUlcer
under-running/ over-sewing or excision
of ulcer radical surgery (gastric resection or
vagotomy)
8/2/2019 Management of Non-Variceal Upper
19/24
While under-running or over-sewing forbleeding ulcers is advisable in a largeproportion of cases, ulcer excision or evenmore radical surgery (e.g. gastric resection
for large, chronic, penetrating gastriculcers) may be performed in selectedcases.
The rebleeding rate was lowest in patientshaving a gastrectomy to include the ulcereither with Billroth I or Billroth IIreconstruction when compared with moreconservative surgery.
8/2/2019 Management of Non-Variceal Upper
20/24
However, the bile leak was followinggastrectomy was much higher and the overallmortality was similar in the two randomizedgroups.
The same study suggested that when ableeding duodenal ulcer is under-run, ligationof the gastroduodenal and right gastroepiploicarteries reduced the rebleeding rate to asimilar level as gastrectomy.
The magnitude of surgery should be tailored tothe type of ulcer, severity of illness in thepatient and experience of the surgeon
8/2/2019 Management of Non-Variceal Upper
21/24
INTERVENTIONALRADIOLOGY In the critical or unstable patient who is not
amenable to immediate surgical interventionradiological intervention appears increasinglyas a very effective option.
In a recent retrospective evaluation ofinterventional embolization therapy over an 8year period, bleeding was stopped in 83% ofcases.
The rate of complications was 14%. Sodium diatrizoate, metal coils, tissue
adhesives and Gelfoam particles were used
8/2/2019 Management of Non-Variceal Upper
22/24
FOLLOW UP
should be discharged with oral proton pumpinhibitors.
Those with gastric ulcers should be re-endoscoped in 6 weeks to assess healing and
rule out malignancy. Attention should be paid to Helicobacter pylori
eradication forall H. pylori positive ulcers. The latter is also recommended for those on
long-termaspirin. Those who need to continue
on NSAIDs should consider COX-2 inhibitors,or the least damaging NSAID with a protonpump inhibitor.
8/2/2019 Management of Non-Variceal Upper
23/24
8/2/2019 Management of Non-Variceal Upper
24/24